Navigation Links
Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
Date:1/4/2012

BALTIMORE, Jan. 4, 2012 /PRNewswire/ -- Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022.  ARC-2022 is being developed by Arcion for pain associated with post-herpetic neuralgia (PHN) and shingles.  ARC-2022 has been evaluated in a single-dose Phase 1 pharmacokinetic study in adult patients with PHN.  The results indicated sustained delivery without requirement of a patch or skin-occlusion.  No safety issues were identified.

"With ARC-2022 our goal is to deliver lidocaine to the skin without the requirement of an occlusive patch.  With topical delivery, systemic toxicities and CNS side effects can be avoided and the abnormal pain signals are suppressed at the point of origination in the skin," said James N. Campbell, MD, President and CEO of Arcion.  "Issues with presently available FDA products for the treatment of neuropathic pain include limited efficacy and frequent side effects.  Patches can pose challenges to the patient, particularly when they must be applied over joints, feet, hands, hairy or sweaty skin, or areas such as the face where aesthetics come into play.  We believe ARC-2022 is an excellent candidate to address a significant market need with a product that optimizes delivery directly to the painful skin without the need for a patch." 

"This patent allowance represents the second patent in the last three months for our two topical chronic pain programs, ARC-2022 and ARC-4558.  These products now have patent protection through 2029 and beyond," commented Kerrie Brady, COO of Arcion. "We are on track to advance ARC-4558 for painful diabetic neuropathy into Phase 3 studies and ARC-2022 into further Phase 1/2 studies in 2012. ARC-4558 has received fast-track status with the FDA."


'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
2. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
3. BioNeutral Group Receives $400,000 in Equity Financing
4. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
5. Intimate Bridge 2 Conception, Inc. Receives $4.3M
6. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
7. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
8. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
9. Watsons Generic Yaz(R) Receives FDA Approval
10. UCSB professor receives award for graphene electronics research
11. iBio, Inc. Receives Notice from NYSE Amex Staff that Company Currently is Below Certain Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Global biostimulants market is expected to reach ... CAGR of 12.5%. In order to cater to ... ecological impacts, farmers are looking to adopt natural ... more effectively & efficiently. Biostimulants are consequently seen ... on investments. , Leading companies in the biostimulants ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Acid Industry is an in-depth research report on ... analysis, the report introduces Palmitic Acid, basic information, ... overview, policy analysis, and news analysis, etc. ... report analyzes Palmitic Acid market in ...
(Date:11/26/2014)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens, today announced that Paul G. Thomas ... Annual Healthcare Conference on December 2, 2014 at 4:30pm ET. ... in New York, NY . ... operations, strategies and prospects may be discussed. To listen to ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... on developing diagnostic tests for cancer and other conditions, today ... be presented at the Science for Business BioWin Day 2014, ... . The data come from VolitionRx,s lung cancer pilot ... department of the Centre Hospitalier Universitaire (CHU) de Liege in ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... , MILFORD, Mass., Dec. 9 ... it has shipped the first units of its ground-breaking SYNAPT(TM) ... American Society of Mass Spectrometry (ASMS) annual conference in Philadelphia ... research centers across Europe, North America and Asia and for ...
... , ... firm announces opening of its Brazilian regional office , ... Chicago, Ill. (Vocus) December 9, 2009 -- As ... globe, The Adventus Group, a world leader in the contaminated soil , sediment ...
... Dec. 8 Dendreon Corporation (Nasdaq: DNDN ) announced ... to market and other conditions, of 15,000,000 shares of its ... Dendreon intends to grant to the underwriters a 30-day ... common stock to cover over-allotments, if any. J. P. ...
Cached Biology Technology:Waters Ships First Units of SYNAPT G2 Mass Spectrometer 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Dendreon Announces Proposed Public Offering of Common Stock 2Dendreon Announces Proposed Public Offering of Common Stock 3
(Date:11/5/2014)... show great diversity in their ability to identify scents ... differ in their perceptual evaluation of odors, with women ... , Sex differences in olfactory detection may play ... connected to one,s perception of smell, which is naturally ... superiority has been suggested to be cognitive or emotional, ...
(Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... to improve low cost methods for carbon capture. Scientists ... national synchrotron to investigate the efficiency of calcium oxide ... results, published in the journal of Energy & ... the key mechanisms involved. This new knowledge will inform ...
... 2012) -- Using mutant zebra fish, researchers studying the earliest ... gotten a look at a mechanism involved in a genetic ... in the Aug. 1 issue of the journal Development ... scrutiny in future research into Fraser syndrome, a many-faceted and ...
... millennia, humans have pondered their mortality and whether death ... an afterlife. Millions of Americans have reported near-death or ... believe in an afterlife, from reincarnation to resurrection and ... abound, but there has been no comprehensive and rigorous, ...
Cached Biology News:Low-cost carbon capture gets X-rayed 2Low-cost carbon capture gets X-rayed 3Study of zebra fish mouth formation may speak to Fraser syndrome hearing loss 2Study of zebra fish mouth formation may speak to Fraser syndrome hearing loss 3$5 million grant awarded to UC Riverside to study immortality 2$5 million grant awarded to UC Riverside to study immortality 3$5 million grant awarded to UC Riverside to study immortality 4
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Phospho-Cyclin D1 (Thr286) Antibody...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: